Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
devdiscourse19m
Healthcare Dynamics: Challenges and Innovations Amid Global Shifts
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
There are dot-com echoes beyond tech. This Costco shareholder explains why returns will be paltry at best.
Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
Hims & Hers posts Q4 beat, issues bullish outlook: why is the stock crashing?
Hims & Hers Health (NYSE:HIMS) fell ~19% in the premarket on Tuesday, even as the telehealth company reported better-than-expected Q4 2024 financials and set its 2025 outlook above consensus during ...